SCHEMBL30110430

CC(=O)N[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](NC(C)=O)C(O)O[C@@H]2CO[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3NC(C)=O)[C@@H](O)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3NC(C)=O)[C@@H]2O)[C@@H]1O

nearest known ligand 0.51

Predicted protein targets (top 16)

	gene	UniProt	supporting neighbours	confidence
▸	LGALS3	P17931	2/20	0.51

▸	LGALS8	O00214	1/20	0.51

▸	LGALS4	P56470	1/20	0.51

▸	CD209	Q9NNX6	2/20	0.51

▸	AMY2A	P04746	4/20	0.49

▸	ENGASE	Q8NFI3	1/20	0.48

▸	HPSE	Q9Y251	2/20	0.44

▸	CHIA	Q9BZP6	1/20	0.43

▸	CD69	Q07108	1/20	0.43

▸	F2	P00734	1/20	0.42

▸	SERPINC1	P01008	1/20	0.42

▸	MAPK1	P28482	2/20	0.41

▸	ALDH1A1	P00352	1/20	0.41

▸	CYP3A4	P08684	1/20	0.41

▸	ALOX15	P16050	1/20	0.41

▸	HSD17B10	Q99714	1/20	0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13427334	0.96	LGALS3 (0.54)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL31700509	0.94	LGALS3 (0.55)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL31700961	0.94	LGALS3 (0.55)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL31154034	0.94	LGALS3 (0.56)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL29510709	0.94	LGALS3 (0.56)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL30943987	0.94	LGALS3 (0.56)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL12871588	0.94	LGALS3 (0.56)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL29383063	0.94	LGALS3 (0.56)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL29407248	0.94	LGALS3 (0.56)	LGALS3LGALS8LGALS4CD209AMY2A
SCHEMBL29370181	0.94	LGALS3 (0.56)	LGALS3LGALS8LGALS4CD209AMY2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-11766481-B2	Glycan modified short interfering RNA	GANNA BIO, INC. (US)	2023-09-26	—	—	US	claimed
US-20240115714-A1	GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES	NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT	2024-04-11	—	—	US	disclosed
US-11766481-B2	Glycan modified short interfering RNA	GANNA BIO, INC. (US)	2023-09-26	—	—	US	disclosed
US-20220387607-A1	GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES	NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT	2022-12-08	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11766481-B2	Glycan modified short interfering RNA	SNRPE, FUT6, ALG8	LGALS3 142/4885LGALS8 65/4885LGALS4 183/4885
US-20220387607-A1	GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES	NSUN3, RNGTT, SIGLEC7	LGALS3 94/4885LGALS8 78/4885LGALS4 149/4885
US-20240115714-A1	GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES	NSUN3, RNGTT, SIGLEC7	LGALS3 94/4885LGALS8 78/4885LGALS4 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.